Year: 2025

SIKA TO ACQUIRE LEADING MORTAR COMPANY IN SWEDEN TO ENHANCE NORDIC PRESENCE AND ACCELERATE GROWTH Sika has agreed to acquire Finja, a leading Swedish manufacturer of a wide range of mortars and integrated solutions that enhance efficiency and sustainability in construction. The acquisition will strengthen Sika’s Nordic presence and provide major cross-selling opportunities through the highly complementary product portfolios and increased presence in the distribution channel. In addition, it will enable substantial capacity expansion, supporting future growth by bringing a wider product offering closer to Nordic customers.  Founded in 1957, Finja is a family-owned, high-performing company with net sales of approximately CHF 60 million. It is recognized as a leading Swedish producer and system provider of a comprehensive range of dry mortars,...

EfTEN Capital AS plans to disclose the financial results of EfTEN United Property Fund in 2026 as follows:02/02/2026        Unaudited results for Q4 2025 and 12 months 2025 04/03/2026        Audited results for 2024 07/05/2026        Q1 interim results 06/08/2026        Q2 interim results 05/11/2026        Q3 interim resultsKristjan TamlaManaging DirectorPhone: 655 9515E-mail: Kristjan.Tamla@eften.ee

EfTEN Real Estate Fund AS plans to publish its financial results and hold the annual general meeting of shareholders in 2026 as follows: 29/01/2026        Unaudited results for Q4 2025 and 12 months 2025 27/02/2026        Audited results for 2025 07/04/2026        Annual General Meeting 30/04/2026        Q1 interim results 30/07/2026        Q2 interim results 29/10/2026        Q3 interim results Marilin HeinCFO                                                                                                                                            Phone: 655 9515                                                                                                                        E-mail: marilin.hein@eften.ee

Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11,  The Lancet – one of the world’s most renowned  academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. This study, led by MD Anderson Cancer Center, the world’s leading hospital for cancer care, is the first-ever randomized controlled trial (RCT) to provide the highest level of evidence demonstrating the benefits of proton therapy over conventional radiotherapy for this indication. Oropharyngeal cancer is a type of head and neck cancer that develops in the throat region,...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisOngoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayedParis, December 15, 2025. Sanofi anticipates that the review process for the ongoing US regulatory review of tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS) will extend beyond the previously communicated US target action date of December 28, 2025, and expects further guidance from the FDA by the end of the first quarter of 2026. In response to an FDA request, Sanofi has submitted an expanded access protocol for tolebrutinib in nrSPMS, underscoring the company’s commitment to providing eligible patients with access to this investigational...

15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the trials for futility following its review of data from a pre-specified interim analysis. Importantly, efgartigimod showed a favorable safety and tolerability profile, and no new safety signals were identified. “We are disappointed the studies did not meet our desired outcome and we especially empathize with...

EfTEN United Property Fund earned a net profit of 236 thousand euros in November and 2,45 million euros in 11 months of 2025 (808 thousand euros the same period last year). The net asset value (NAV) of the fund unit was 11,31 euros at the end of November, increasing by 0,8% per month. If the fund’s investment in the EfTEN Real Estate Fund AS share were to be recorded on the basis of its net asset value, the NAV of EfTEN United Property Fund would be 11,44 euros, increasing by 0,9% per month. In Invego Uus-Järveküla OÜ, where the fund has an 80% ownership, clients booked six terraced houses to be completed in early 2026 and purchased (entered into a real right contract) three terraced houses that had already been completed. In November, the development company earned a profit of 137 thousand euros and EfTEN United Property Fund also...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo The safety profile of tolebrutinib was consistent with previous studiesParis, December 15, 2025. Results from the PERSEUS phase 3 study (clinical study identifier: NCT04458051) showed that tolebrutinib did not meet its primary endpoint in delaying time to 6-month composite confirmed disability progression (cCDP) in participants with primary progressive multiple sclerosis (PPMS), which represents 10% of the overall multiple sclerosis patient population. Based on these results, Sanofi will not pursue regulatory registration for PPMS. “We are disappointed...

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update:Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX Officially Enters the Forida Market with the Signing of Golden Hills Investment LLC who Made a Deposit Agreement for 2,000 FX Super One MPVsThe FX Super One First Pre-Production Vehicles Roll-off Ceremony is scheduled for December 21 at the Company’s manufacturing facility in Hanford, CA. FX has entered the Florida market with the signing of Golden Hills Investment LLC, a Florida-based high-end vacation rental investor and operator company. They made a deposit agreement for 2,000 FX Super One MPV’s, including non-refundable deposits and non-binding pre-orders.LOS ANGELES, Dec. 14, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”,...

– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join the call. The call can also be accessed via live webcast....